We investigated the combined impact of genetic variants in the glucokinase regulatory protein gene (GCKR) and fibroblast growth factor 21 (FGF21), together with circulating FGF21 concentrations, on susceptibility to MASLD and its progression to MASH. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.